Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Intron Biotechnology Inc patents


Recent patent applications related to Intron Biotechnology Inc. Intron Biotechnology Inc is listed as an Agent/Assignee. Note: Intron Biotechnology Inc may have other listings under different names/spellings. We're not affiliated with Intron Biotechnology Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Intron Biotechnology Inc-related inventors


Novel lactobacillus plantarum bacteriophage lac-plp-1 and use thereof for inhibiting lactobacillus plantarum proliferation

The present invention relates to a siphoviridae bacteriophage lac-plp-1 that is isolated from the nature and can kill lactobacillus plantarum cells specifically, which has a genome represented by the nucleotide sequence of seq. Id. ... Intron Biotechnology Inc

Novel peptide compound, production method therefor, and use thereof

Provided are a novel peptide compound, a method of producing the same, and use of the peptide compound. Since the peptide compound has anticancer activity, the peptide compound may be used for the prevention or treatment of cancer.. ... Intron Biotechnology Inc

Novel lactococcus garvieae bacteriophage lac-gap-1 and use thereof in suppressing proliferation of lactococcus garvieae bacteria

The present invention relates to a myoviridae bacteriophage lac-gap-1 that is isolated from the nature and can kill specifically lactococcus garvieae cells, which has a genome represented by the nucleotide sequence of seq. Id. ... Intron Biotechnology Inc

Novel lactobacillus brevis bacteriophage lac-brp-1 and use thereof for inhibiting lactobacillus brevis proliferation

The present invention relates to a siphoviridae bacteriophage lac-brp-1 that is isolated from the nature and can kill lactobacillus brevis cells specifically, which has a genome represented by the nucleotide sequence of seq. Id. ... Intron Biotechnology Inc

Novel enteropathogenic e. coli bacteriophage esc-chp-2 and use thereof for inhibiting proliferation of enteropathogenic e. coli

The present invention relates to a myoviridae bacteriophage esc-chp-2 that is isolated from the nature and can kill specifically enteropathogenic e. Coli strains, which has a genome represented by the nucleotide sequence of seq. ... Intron Biotechnology Inc

Novel shigatoxin-producing f18 type e. coli bacteriophage esc-cop-1 and use thereof for inhibiting proliferation of shigatoxin-producing f18 type e. coli

The present invention relates to a myoviridae bacteriophage esc-cop-1 that is isolated from the nature and can kill specifically shigatoxin-producing type f18 e. Coli strains, which has a genome represented by the nucleotide sequence of seq. ... Intron Biotechnology Inc

Novel clostridium perfringens bacteriophage clo-pep-1 and use thereof for inhibiting proliferation of clostridium perfringens

The present invention relates to a myoviridae bacteriophage clo-pep-1 that is isolated from the nature and can kill clostridium perfringens cells specifically, which has the genome represented by nucleotide sequence of seq. Id. ... Intron Biotechnology Inc

Novel enteroinvasive e. coli bacteriophage esc-cop-4 and use thereof for inhibiting proliferation of enteroinvasive e. coli

The present invention relates to a myoviridae bacteriophage esc-cop-4 that is isolated from the nature and can kill specifically enteroinvasive e. Coli strains, which has a genome represented by the nucleotide sequence of seq. ... Intron Biotechnology Inc

Novel enterohemorrhagic e. coli bacteriophage esc-chp-1 and use thereof for inhibiting proliferation of enterohemorrhagic e. coli

The present invention relates to a myoviridae bacteriophage esc-chp-1 that is isolated from the nature and can kill specifically enterohemorrhagic e. Coli strains, which has a genome represented by the nucleotide sequence of seq. ... Intron Biotechnology Inc

Fk506 derivative maintaining nerve regeneration activity without immunosuppressive activity, and use thereof

The present invention relates to an fk506 derivative which has reduced immunosuppressive activity but maintains nerve regeneration activity, a preparing method thereof, and a pharmaceutical composition comprising the same for preventing or treating nervous system diseases. A composition comprising 9-deoxo-prolyl-fk506, 31-o-demethyl-fk506, or 9-deoxo-31-o-demethyl-fk506 can promote nerve regeneration and has reduced immunosuppressive activity, thereby reducing side effects in the treatment of nervous system diseases.. ... Intron Biotechnology Inc

Pharmaceutical composition containing fk506 derivative for treating fungal infection caused by genus cryptococcus and genus candida and use thereof

The present invention relates to a pharmaceutical composition containing fk506 derivative for treating a fungal infection caused by the genus cryptococcus or the genus candida, and a use thereof. In addition, the present invention relates to a therapeutic agent for fungal infection caused by the genus cryptococcus or the genus candida, the therapeutic agent containing fk506 derivative. ... Intron Biotechnology Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Intron Biotechnology Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Intron Biotechnology Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###